FAM168A and hepatocellular carcinoma: Decreases TCRP1 (tongue-cancer-resistance-associated protein 1) and p-AKT levels, increases LC3 II levels, and decreases Beclin-1 levels in hepatocellular carcinoma (HepG2 and SMMC-7721)